目的: 探讨经颅微电流刺激疗法(CES)治疗躯体形式障碍的临床辅助效果。方法: 选取2018年10月-2019年12月于本院住院治疗的62例躯体形式障碍患者,随机分为研究组与对照组,对照组采用文拉法辛缓释剂治疗,研究组采用文拉法辛缓释剂联合经颅微电流刺激疗法(CES),治疗前与治疗后采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、症状自评量表(SCL-90)、躯体化症状自评量表(SSS)来评估临床疗效及不良反应发生情况。结果: 研究组的临床疗效显著优于对照组(χ2=2.132,P＜0.05);与治疗前比较,治疗后2、4及8周时两组患者HAMD评分、HAMA评分、SCL-90评分和SSS评分均显著降低;治疗2、4及8周时研究组患者的HAMD、HAMA评分均显著低于对照组(t1=4.636,t2=2.159,P＜0.05;t1=6.207,t2=4.693,P＜0.001;t1=3.224,t2=3.414,P＜0.01);治疗2、4及8周时,研究组患者SCL-90评分显著低于对照组(t1=5.201,t2=7.006,t3=6.374,P＜0.001),且SSS评分也显著低于对照组(t1=2.803,t2=2.834,t3=3.485,P＜0.01);研究组不良反应的总发生率为35.48 %,对照组为63.33 %,研究组不良反应总发生率显著低于对照组(χ2=4.731,P＜0.05)。结论: 与仅应用文拉法辛缓释剂相比,经颅微电流刺激疗法联合文拉法辛缓释剂治疗患者的躯体形式障碍有显著的优势,值得临床推广和应用。
Objective: To investigate the effects of cranial electrotherapy stimulation combined with capsules. Methods: A total of 62 patients with somatoform disorders in our hospital from October 2018 to December 2019 were selected. A total of 62 patients were randomly divided into study group and control group. The control group was treated with capsules, and the study group was treated with capsules combined with cranial electrotherapy stimulation. HAMD, HAMA, SCL-90 and SSS were used to evaluate the clinical efficacy and the occurrence of adverse reactions before and after treatment. Results: The clinical efficacy of the study group was significantly better than that of the control group(2=2.132,P＜0.05); HAMD, HAMA , SCL-90 and SSS of two groups were significantly decreased after 2, 4 and 8 weeks of treatment. HAMD and HAMA in the study group were significantly lower than those in the control group 2, 4 and 8 weeks of treatment(t1=4.636,t2=2.159, P＜0.05; t1=6.207,t2=4.693, P＜0.001; t1=3.224,t2=3.414, P＜0.01); 2, 4 and 8 weeks of treatment, SCL-90 in the study group was significantly lower than that in the control group(t1=5.201,t2=7.006,t3=6.374, P＜0.001), and the SSS was significantly lower than the control group(t1=2.803,t2=2.834,t3=3.485, P＜0.01). The total incidence of adverse reactions was 35.48 % in the study group and 63.33 % in the control group, and the difference was statistical significant (χ2=4.731, P＜0.05). Conclusion: Cranial electrotherapy stimulation combined with capsules has significant advantages in the treatment of patients with somatoform disorders, which is worthy of clinical promotion and application.
[1] Kroenke K, Rosmalen JGM. Symptoms, syndromes, and the value of psychiatric diagnostics in patients who have functional somatic disorders[J]. Med Clin North Am, 2006, 90(4): 603-626.
[2] Lankes F, Schiekofer S, Eichhammer P, et al. The effect of alexithymia and depressive feelings on pain perception in somatoform pain disorder[J]. J Psychosom Res, 2020, 133: 110101.
[3] 洪丹. 文拉法辛缓释片联合奥氮平治疗躯体形式障碍的疗效分析[J]. 中国现代药物应用, 2018, 12(18): 127-128.
[4] Smith RB. Microcurrent therapies: emerging theories of physiological information processing[J]. Neuro Rehabilitation, 2002, 17(1): 3-7.
[5] 王芸, 王高华, 王惠玲, 等. 躯体形式障碍患者注意偏向与躯体症状的关联[J]. 中国临床心理学杂志, 2019, 27(1): 14-17.
[6] 马希权, 张岚, 张耀尹, 等. 综合医院门诊躯体形式障碍患者功能损害及相关影响因素[J]. 中华精神科杂志, 2019, 52(4): 241-246.
[7] 吴晓娜, 麦麦提·如孜, 赵国富, 等. 某综合医院急诊科精神障碍收治情况的现状调查[J]. 国际精神病学杂志, 2019, 46(2): 293-296.
[8] 万礼霞, 朱相华, 胡存昆, 等. 躯体形式障碍患者社会支持与功能失调性认知?人格障碍倾向的相关性研究[J]. 中华行为医学与脑科学杂志, 2020, 29(5): 448-452.
[9] Kroenke K, Messina N 3rd, Benattia I, et al. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder[J]. J Clin Psychiatry, 2006, 67(1): 72-80.
[10] 史少丽, 赫利寒. 文拉法辛联合生物反馈治疗躯体形式障碍的对照研究[J]. 精神医学杂志, 2016, 29(4): 284-286.
[11] 茅卫兵, 曲万仁, 邱建成. 正念干预躯体形式障碍患者临床效果的Meta分析[J]. 精神医学杂志, 2019, 32(1): 18-21.
[12] 史昊楠, 谢瑛, 桂沛君, 等. 应用经颅微电流刺激治疗对青年失眠的临床疗效观察[J]. 临床和实验医学杂志, 2019, 18(19): 2106-2109.
[13] 冯少慧, 谢琴, 姜文娟, 等. 经颅微电流刺激辅助文拉法辛治疗广泛性焦虑症的疗效观察[J]. 中华物理医学与康复杂志, 2012, 34(1): 38-40.
[14] 于相芬, 孙宇新, 孙振晓. 文拉法辛的不良反应认识进展(下)[J]. 中国药物滥用防治杂志, 2018, 24(1): 39-42, 44.
